This webinar will provide attendees with the knowledge and skills needed to develop and produce an OTC drug product for marketing and sale in the U.S.
The Food and Drug Administration and the Consumer Product Safety Commission have regulations pertaining to OTC drugs. The U.S. Food and Drug Administration's (FDA) is responsible for the regulation and oversight of the U.S. OTC drug market. Congress has granted FDA regulatory authority over the formulation, manufacturing, labeling, marketing and promotion; and import / export of OTC drug products into the U.S. Under this current regulatory regime, there are 4 pathways that a company may follow to enter the OTC drug market including (a) following an appropriate Drug Monograph; (b) with an Agency approved New Drug Application (NDA); (c) via the currently popular Rx-to-OTC Switch Process or (d) via an ANDA citing a previously-approved product.
WHY SHOULD YOU ATTEND?
This webinar will discuss U.S. FDA and Consumer Product Safety Commission regulation of OTC drug products and strategic recommendations for mitigating the risk of enforcement action in the future. Attendees will gain an understanding of various available options for producing and selling an OTC drug product. FDA and CPSC requirements for OTC drugs will be covered. There will also be some discussion of the market differences between Rx and OTC products.
AREA COVERED
- Claims for drugs, devices, medical foods and cosmetics
- NDA, ANDA and OTC Monographs for OTC Drugs
- Rx to OTC Switches
- cGMPs for OTC drugs
- Tamper Evidence and Poison Control
- Branded Innovator, Branded Generic and Generics
LEARNING OBJECTIVES
- Gain a comprehensive understanding of how OTC drug products are regulated in the U.S
- Learn to distinguish between a potential Rx pharmaceutical product and an OTC drug
- Recognize the difference between the various pathways for commercializing an OTC drug product
- Understand how to identify and successfully navigate an OTC Drug Monograph
- Recognize when reliance on a Proposed Rule, Final Rule and/or Drug Monograph is appropriate
- Understand how to determine whether an Ingredient is considered Safe or GRAS/E for use in an OTC drug and understand the difference between Category I, II and II Ingredient designations
- Identify the required elements of a compliant OTC Drug Label
- Take away strategies for marketing and promoting OTC drug products, and for mitigating potential enforcement risks
- Possess a working knowledge of the Rx-to-OTC Switch Process
- Review and evaluate several of FDA's current OTC Monographs
WHO WILL BENEFIT?
- Regulatory affairs managers, directors and associates
- Compliance specialists
- Marketing managers
- Quality professionals
- Document control specialists
- Record retention specialists
- Senior Managers / Business Owners
- Product Managers
- Labeling and Artwork Designers
- Regulatory and Quality Professionals
- Sales and Marketing Managers
- R&D Managers and Staff
This webinar will discuss U.S. FDA and Consumer Product Safety Commission regulation of OTC drug products and strategic recommendations for mitigating the risk of enforcement action in the future. Attendees will gain an understanding of various available options for producing and selling an OTC drug product. FDA and CPSC requirements for OTC drugs will be covered. There will also be some discussion of the market differences between Rx and OTC products.
- Claims for drugs, devices, medical foods and cosmetics
- NDA, ANDA and OTC Monographs for OTC Drugs
- Rx to OTC Switches
- cGMPs for OTC drugs
- Tamper Evidence and Poison Control
- Branded Innovator, Branded Generic and Generics
- Gain a comprehensive understanding of how OTC drug products are regulated in the U.S
- Learn to distinguish between a potential Rx pharmaceutical product and an OTC drug
- Recognize the difference between the various pathways for commercializing an OTC drug product
- Understand how to identify and successfully navigate an OTC Drug Monograph
- Recognize when reliance on a Proposed Rule, Final Rule and/or Drug Monograph is appropriate
- Understand how to determine whether an Ingredient is considered Safe or GRAS/E for use in an OTC drug and understand the difference between Category I, II and II Ingredient designations
- Identify the required elements of a compliant OTC Drug Label
- Take away strategies for marketing and promoting OTC drug products, and for mitigating potential enforcement risks
- Possess a working knowledge of the Rx-to-OTC Switch Process
- Review and evaluate several of FDA's current OTC Monographs
- Regulatory affairs managers, directors and associates
- Compliance specialists
- Marketing managers
- Quality professionals
- Document control specialists
- Record retention specialists
- Senior Managers / Business Owners
- Product Managers
- Labeling and Artwork Designers
- Regulatory and Quality Professionals
- Sales and Marketing Managers
- R&D Managers and Staff
Speaker Profile

Dr. Loren Gelber has worked in the pharmaceutical industry for more than 40 years, at both the FDA and in private industry. She has prepared more than 50 submissions to the FDA. Her specialty is compliance with US regulatory requirements. She has a BA in Biology, an MS in Chemistry and a Ph.D. in Medicinal Chemistry.
Upcoming Webinars

Interactive dashboards & analytics in Excel

Copilot and HR: An Introduction for HR Professionals

4-Hour Virtual Seminar on Bootcamp on Excel

Leading Across Generations: 5 Challenges & 10 Strategies to…


I-9 Audits: Strengthening Your Immigration Compliance Strat…

Fair Lending in 2025: New Regulations, Examinations and Enf…


Tattoos, hijabs, piercings, and pink hair: The challenges …

Using Emotional Intelligence to Elevate Your Leadership

ChatGPT & HR: How HR Recruiting Professionals Can Leverage …

FDA Trends in Compliance and Enforcement in Computer System…

Elevate Your Workplace Wellness: 10 Critical Wellness Facto…

How to Manage the Legal Landmine of the FMLA, ADA and Worke…

How to Write a Successful Job Hazard Analysis


How to Write Right for Better Business Communication

How to Prepare For and Host a FDA Inspection and Respond to…

Public Speaking: Overcoming The Fear of Public Speaking

From Good to Great: The Secrets to an Optimized LinkedIn Pr…



Workplace Investigations 101: How to Conduct your Investiga…

Policy Pops: Navigating DEI in the 2025 Workplace: Strategi…

The Five Cs Of Commercial Credit: The Basic Elements Of Cre…

Transforming Anger And Conflict Into Collaborative Problem …


Navigating Alcohol and Drug Addiction Protections Under the…


Reduce Stress in the Workplace: Effective Ways to Handle Co…



Transforming HR with AI: Unlocking Excellence and Innovation

Creating Employee Handbooks that Protect You and Support th…

FDA Technology Modernization Action Plan (TMAP) and Impact …


Transform Data into Insights: A Beginners Guide to Excel Pi…


Mindful Communication:The Key to Meaningful Conversations i…

FDA Proposes Framework to Advance Credibility of AI Models

50+ new Excel features so far this decade

FMLA Compliance in 2025: A Comprehensive Guide & Strategies…

Excel - 10 Key Worksheet Functions to Skyrocket Your Produc…

Managing Toxic Employees: Strategies For Leaders To Effecti…

Hiring and Retaining Employees in this Crazy Economy

Harassment, Bullying, Gossip, Confrontational and Disruptiv…